Company intelligence / Profile preview

Digna Biotech S.L.

Ownership: Private
Development stage: Other

Overview

The company has conducted clinical trials for acute intermittent porphyria using gene therapy and has received FDA Orphan Drug status for cardiotrophin-1 for acute liver failure treatment. Currently has at least one drug in Phase 2 trials.

Therapeutic areas: GastroenterologyNeurologyRare DiseasesCardiovascular
Modalities: CytokinesGene therapy
Industry: Biotech

Drug pipeline

5 assets

disitertide

4 more assets in the full pipeline.

Request access →

Partnerships

Biotecnol Ltd.

Beyond the preview

Go deeper on Digna Biotech S.L..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Digna Biotech S.L..

Explore the full profile